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In Brief
Hippo signaling is a conserved kinase
cascade that mediates transcription
through a Yap65/Taz-Tead complex and
governs organ size. Manderfield et al.
have identified Yap65 and Taz as coacti-
vators of Pax factors and established
neural crest as a novel site of Hippo
signaling. The Pax3-Yap65/Taz complex
is regulated by upstream Hippo kinases
and is Tead independent. Deletion of
Yap65 and Taz in neural crest generated
differentiation defects in specific neural
crest derivatives.
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Loss of Pax3, a developmentally regulated transcrip-
tion factor expressed in premigratory neural crest,
results in severe developmental defects and embry-
onic lethality. Although Pax3 mutations produce
profound phenotypes, the intrinsic transcriptional
activation exhibited by Pax3 is surprisingly modest.
We postulated the existence of transcriptional co-
activators that function with Pax3 to mediate de-
velopmental functions. A high-throughput screen
identified the Hippo effector proteins Taz and
Yap65 as Pax3 coactivators. Synergistic coactivation
of target genes by Pax3-Taz/Yap65 requires DNA
binding by Pax3, is Tead independent, and is regu-
lated by Hippo kinases Mst1 and Lats2. In vivo,
Pax3 and Yap65 colocalize in the nucleus of neural
crest progenitors in the dorsal neural tube. Neural
crest deletion of Taz and Yap65 results in embryo-le-
thal neural crest defects and decreased expression
of the Pax3 target gene, Mitf. These results suggest
that Pax3 activity is regulated by the Hippo pathway
and that Pax factors are Hippo effectors.
INTRODUCTION
Neural crest is a multipotent population of cells arising from the
embryonic dorsal neural tube. Following neural tube closure,
neural crest cells undergo an epithelial-mesenchymal transition
(EMT), migrate along defined routes, and contribute to multiple
organs and tissues including craniofacial cartilage, bone, and
the pigmented cells of the skin (melanocytes). Neural crest in-
duction is dependent upon inductive signals from neighboring
tissues. Wnt and Bmp signaling has been implicated in this
process, though the precise details of how inductive signals
result in EMT, migration, and cell specification remain to be
elucidated.
Pax3 plays a critical role in premigratory neural crest and is
thought to orchestrate neural crest-specific gene expression
(Goulding et al., 1991). Mutation of Pax3 in the mouse resultsCell Rein embryonic lethality and a wide array of neural crest abnormal-
ities, including pigmentation defects and congenital heart dis-
ease. In the melanocyte lineage, Pax3 functions with Sox10 to
directly activate the expression of microphthalmia-associated
transcription factor (Mitf), which is required for melanogenesis.
In humans, PAX3 mutations result in Waardenburg syndrome,
characterized by pigmentation defects and deafness due to neu-
ral crest deficiencies.
Other members of the Pax family, consisting of nine related
factors inmammals, are expressed in various organs and tissues,
where they play critical roles in organogenesis. Pax transcription
factors are characterized by the presence of a DNA-binding
domain termed the paired domain that mediates sequence-spe-
cific protein-DNA interactions (Chi and Epstein, 2002). Although
Pax genes also encode a C-terminal transactivation domain,
in vitro assays reveal relatively weak intrinsic activation capacity.
The transactivation potential of Pax factorsmay bemodulated by
interacting proteins. For example, a Pax3/Pax7 binding protein,
Pax3/7BP, can recruit H3K4 histone methyltransferase activity
to Pax target genes in C2C12 myoblasts, thus regulating cell
proliferation and the expression of the Pax target genes Id3 and
Cdc20 (Diao et al., 2012). Pax6 can interact with homeodo-
main-interacting protein kinase 2 (Hipk2). Hipk2 phosphorylates
Pax6 and enhances Pax6 interaction with p300, thereby in-
creasing transcriptional activation (Kim et al., 2006). However,
the functional role of Pax interacting factors has not been exam-
ined in detail in vivo.
The Hippo signaling pathway is a kinase cascade, initially
identified in Drosophila, that governs overall organ size through
regulation of proliferation and apoptosis (Justice et al., 1995; Xu
et al., 1995; Tapon et al., 2002; Harvey et al., 2003; Wu et al.,
2003). Following the identification in Drosophila, mammalian
Hippo signaling molecules have been defined. The upstream
kinases Mst1 and Mst2 interact with a scaffolding protein Salva-
dore1. Mst1 and Mst2 phosphorylate the downstream kinases
Lats1 and Lats2 along with associated scaffolding proteins
Mobkl1A/Mobkl1b. Lats1 and Lats2 phosphorylate downstream
effector molecules of the Hippo pathway, Taz and Yap65. When
Hippo signaling is inactive, Taz and Yap65 are dephosphory-
lated, located in the nucleus, and act as transcriptional coacti-
vators. Canonical transcriptional activation is achieved through
association with Tead factors that serve as the DNA-bindingports 9, 1885–1895, December 11, 2014 ª2014 The Authors 1885
Figure 1. Pax3 Transcriptional Activity Is
Significantly Increased in the Presence of
Taz or Yap65, and the Activation Is Tead1 In-
dependent
(A) Results of dual luciferase reporter assays in
HEK293T cells with Pax3-PairedDomain (PD)-
luciferase reporter in the presence (+) or absence
() of Pax3, Taz, or Yap65.
(B) Results of dual luciferase reporter assays in
HEK293T cells with Pax3-HomeoDomain (HD)-
luciferase reporter in the presence (+) or absence
() of Pax3, Taz, or Yap65.
(C) Results of dual luciferase reporter assays in
HEK293T cells with Pax3-PD-luciferase reporter in
the presence (+) or absence () of Pax3, Pax3-PD
Mutant, Taz, or Yap65.
(D) Results of dual luciferase reporter assays
in HEK293T cells with Pax3-PD-luciferase re-
porter in the presence (+) or absence () of
Pax3, Taz, or the specified nanogram amount of
DN-Tead1.
(E) Results of dual luciferase reporter assays in
HEK293T cells with 8xGTIIC-luciferase reporter in
the presence (+) or absence () of Taz or the
specified nanogram amount of dominant-negative
Tead1 (DN-Tead1).
(F) Results of dual luciferase reporter assays in
HEK293T cells with Pax3-PD-luciferase reporter in the presence (+) or absence () of Pax7, Taz, or the specified nanogram amount of DN-Tead1.
In all experiments, luciferase activity was first normalized to the activity of a cotransfected renilla luciferase construct, then to the activity observed in the absence
of specified cDNAs (lane 1). All experiments were performed in duplicate on a minimum of three individual occasions. Data depicted are the mean + SEM.
Statistics were completed using an ANOVA with a Tukey-Kramer post hoc comparison test. ***p < 0.001, *p < 0.05.partners for Taz and Yap65. Following activation of the Hippo
pathway, Taz and Yap65 are phosphorylated and sequestered
in the cytoplasm, thus abrogating transcriptional coactivation.
In addition to Tead factors, Taz and Yap65 are capable of inter-
acting in vitro with other proteins including Runx2, ErbB4, p63/
p73, Tbx5, and Smad-1/2/3/7 (Zaidi et al., 2004; Komuro et al.,
2003; Strano et al., 2001; Alarco´n et al., 2009; Murakami et al.,
2005, Varelas et al., 2008; Ferrigno et al., 2002). We and others
have previously shown that Taz/Yap65, via interaction with
Tead, can contribute to regulation of Pax3 gene expression in
premigratory neural crest (Milewski et al., 2004; Degenhardt
et al., 2010; Gee et al., 2011), and Taz was also identified as
a Pax3-interacting protein in a yeast two-hybrid assay (Mura-
kami et al., 2006). Interestingly, Hippo signaling has been
shown to promote cellular proliferation and EMT (Lei et al.,
2008), two processes critical for the in vivo function of neural
crest.
In this article, we demonstrate a potent, synergistic activation
of target genes by Pax3 and Taz/Yap65. Target gene activation
requires an intact Pax3 DNA-binding domain and is Tead in-
dependent. Hippo kinases, Mst1 and Lats2, can inhibit the tran-
scriptional activity of the complex, demonstrating a role for
Hippo signaling. Pax3 and Yap65 are coexpressed in the dorsal
neural tube at the time of neural crest delamination. Loss of Taz/
Yap65 in these premigratory neural crest cells results in downre-
gulation of Mitf, a target of coordinated Pax-Hippo signaling.
Other members of the Pax family are also coactivated by Taz/
Yap65, suggesting that one output of Hippo signaling is activa-
tion of Pax targets.1886 Cell Reports 9, 1885–1895, December 11, 2014 ª2014 The AutRESULTS
A High-Throughput Screen Identifies Taz and Yap65 as
Pax3 Coactivators
To identify potential Pax3 coactivator molecules, we conducted a
high-throughput screen by cotransfecting a Pax3 expression
plasmid along with a Pax3 luciferase reporter vector with each
of 15,000 human and mouse cDNAs arrayed in 384-well plates
in human embryonic kidney 293T (HEK293T) cells (Mammalian
Gene Collection MGCv1 library, Open BioSystems). The Pax3 re-
porter contains five Pax3 paired-domain DNA binding sequences
(Epstein et al., 1994) upstream of a synthetic minimal promoter di-
recting firefly luciferase expression. Potential Pax3 coactivators
were identified as cDNAs that generated luciferase activity
greater than that of Pax3 alone. Both Taz and Yap65 were identi-
fied among the top five coactivators (Table S1).Weconfirmed that
Pax3 can interact with Yap65, like Taz (Murakami et al., 2006),
using the Duolink system, which utilizes a proximity ligation assay
to monitor protein-protein interactions in situ (Figure S1A). Inde-
pendent validation experiments in HEK293T cells confirmed the
ability of either Taz or Yap65 to induce synergistic transactivation
of the synthetic Pax3 luciferase reporter when transfected with
Pax3 (Figure 1A). When Pax3, Taz, or Yap65 was expressed inde-
pendently, each induced only4- to 5-fold activation. In contrast,
when Pax3 was coexpressed with either Taz or Yap65, over
60-fold activation was induced (Figure 1A). The nine mammalian
Pax genes can be divided into four families based upon sequence
conservation, and members of each Pax subfamily can function
synergistically with Taz and Yap65 (Figure S1).hors
Several Pax family members, including Pax3, contain a home-
odomain DNA binding domain in addition to the paired domain,
and Pax3 can occupy both paired and homeodomain recognition
motifs in vivo (Soleimani et al., 2012). To determine if the pres-
ence of Taz or Yap65 enhances Pax3 activation at homeodomain
sequences, we generated a Pax-homeodomain luciferase re-
porter containing ninePax homeodomainDNAbindingmotifs up-
stream of a synthetic minimal promoter directing firefly luciferase
expression. Pax3 could synergize with either Taz or Yap65 to
activate the synthetic homeodomain reporter (Figure 1B).
Pax3-Taz/Yap65 Activation Requires Pax3 DNA Binding
and Is Tead Independent
Taz and Yap65 are generally thought to act by interacting with
Tead factors, which are expressed ubiquitously, although alterna-
tive DNA binding proteins have been described to interact with
Taz or Yap65 in vitro (Zhang et al., 2009; Zhao et al., 2008; Zaidi
et al., 2004; Komuro et al., 2003; Strano et al., 2001; Murakami
et al., 2006). To establish if DNA binding by Pax3 is required for
transcriptional coactivation observed in our assays, we examined
the effect of amissensemutation in the Pax3 paired domain found
in a patient with Waardenburg syndrome that impairs sequence-
specific DNA interactions (Epstein et al., 1995). The Pax3 DNA
binding mutant (Pax3-PD Mutant) was unable to synergize with
either Taz or Yap65 (Figure 1C). These data suggest that Pax3
must associate with DNA to mediate the robust activation
observed in the presence of Taz and/or Yap65. The Pax3-PD
Mutant was able to synergize with Taz or Yap65 when a homeo-
domain reporter was used and protein expression was confirmed
by immunoblot (Figure S2). Furthermore, inhibition of Tead activity
by expression of a dominant-negative Tead mutant (DN-Tead1)
consisting of a truncated protein that retains DNA-binding capac-
ity but cannot recruit Taz (Zhang et al., 2009; Zhao et al., 2008)
failed to prevent Pax3 synergy with Taz (Figure 1D), although it
efficiently abolished Taz activation of a Tead-dependent reporter
(Figure 1E). Pax7, which is closely related to Pax3 and is coex-
pressed in the dorsal neural tube, can also synergize with Taz in
a Tead-independent manner (Figure 1F). Thus, we infer that Taz
and Yap65 can act as direct coactivators of Pax3/7 target genes.
Pax3 and Yap65 Colocalize in the Dorsal Neural Tube
Pax3 is actively transcribed in the dorsal neural tube during early/
midgestation (approximately embryonic day 8 [E8] to E10) when
neural crest cells undergo an epithelial-to-mesenchymal transi-
tion, delaminate, and migrate throughout the body (Goulding
et al., 1991). Yap65 is ubiquitously expressed at similar stages
(Morin-Kensicki et al., 2006). At E9.5 we observed Pax3 and
Yap65 nuclear colocalization in the dorsal neural tube (Figure 2),
dorsal root ganglia, which is derived from the neural crest (Fig-
ure 2A, asterisk), and somites (Figure 2H). Within the dorsal neu-
ral tube, Pax3 and Yap65 are colocalized in the dorsalmost
aspect, the site at which neural crest cells undergo EMT and
delaminate prior to migration. At E10.5 (Figures 2E–2G) and
E11.5 (Figures 2I–2K), phosphorylated Yap65 becomes promi-
nent (Figures 2G and 2K) and nuclear Yap65 is greatly reduced
(Figures 2F and 2J), indicating activation of Hippo signaling.
Thus, Pax3 and Yap65 are colocalized in the nucleus of premi-
gratory neural crest cells.Cell ReLoss of Taz and Yap in Neural Crest Results in
Craniofacial Defects and Downregulation of Mitf
To examine the biological significance of Taz and Yap65 in the
neural crest, floxed alleles were utilized to delete Taz and
Yap65 in premigratory neural crest using Wnt1-Cre (Xin et al.,
2011, 2013). Genotyping of 76 postnatal day 10 (P10) pups re-
sulting from Wnt1-Cre; Tazflox/+;Yapflox/+ x Tazflox/flox;Yapflox/flox
crosses identified no surviving Wnt1-Cre;Tazflox/flox;Yapflox/flox
or Wnt1-Cre;Tazflox/+;Yapflox/flox mice and five of nine surviving
Wnt1-Cre;Tazflox/flox;Yapflox/+ mice had craniofacial defects (Ta-
ble 1). Further analysis of genotype frequencies at various stages
of gestation indicated that Wnt1-Cre;Tazflox/flox;Yapflox/flox
embryos undergo fetal demise prior to E11.5, although they
were identified at the expected frequency at E9.5 (Table 1)
when they appeared grossly normal (Figures 3A–3D). At E10.5,
13 of 13Wnt1-Cre;Tazflox/flox;Yapflox/flox embryos exhibited overt
craniofacial defects (Table 1; Figure 3). Within the neural tubes of
the E10.5 Yap65/Taz deletion embryos, there was no detectable
change in the percentage of proliferating or apoptotic cells (Fig-
ure S3). Grossly, hemorrhages were evident in the branchial arch
regions in the Yap65/Taz double-null embryos (Figures 3Q and
3R). Histologic analysis revealed deficiencies of facial mesen-
chyme in the maxillary and mandibular branchial arches (Figures
3S and 3T), regions normally populated by neural crest. Deletion
of both Yap65 alleles and a single Taz allele resulted in a similar
hemorrhagic phenotype (Figures 3M and 3N), although facial
mesenchyme appeared intact (Figures 3O and 3P), and mice
of this genotype were not identified postnatally (Table 1). In em-
bryos in which both Taz alleles and a single Yap65 allele were
removed, the embryos were phenotypically normal at E10.5 (Fig-
ures 3I–3L) and they survived postnatally (Table 1).
We followed the fate of neural crest cells with or without Yap65
and Taz by including a R26tdTomato (R26Tom/+) Cre reporter
allele. Wnt1-derived cells can be identified in resultant embryos
by expression of tdTomato and detection with an anti-red fluo-
rescent protein antibody. Examination of control and double-
mutant embryos at E10.5 showed that neural crest migration
was grossly intact (Figure 4). Neural crest derivatives populated
the branchial arches and peripheral ganglia (Figures 4B and 4E),
and Pax3 expression was maintained in double-null embryos
(Figures 4C and 4F). Serial sections of fate-mapped E10.5 em-
bryos revealed intact migration of neural crest throughout the
embryo, where they populated regions of presumptive facial
mesenchyme, the peripheral nervous system, and the enteric
ganglia (Figures 4G, 4H, 4L, and 4M). Neurofilament expression
by neural crest-populating peripheral ganglia appeared normal,
as determined by costaining of fate-mapped neural crest cells
with the 2H3 anti-neurofilament antibody (Figures 4I, 4J, 4N,
and 4O). Enteric ganglia derivatives expressed Sox10 at levels
indistinguishable from controls (Figures 4K and 4P). Thus,
many aspects of neural crest migration and fate specification ap-
peared intact despite the loss of Taz/Yap65.
Mitf Is Coordinately Regulated by Pax3 and Yap/Taz
Neural crest-derived cells were also observed adjacent to sur-
face ectoderm in both control and double null-embryos where
migrating melanoblasts are normally found (Figures 5A and 5B).
In control embryos, these cells expressed Mitf, a transcriptionalports 9, 1885–1895, December 11, 2014 ª2014 The Authors 1887
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Figure 2. Pax3 and Yap65 Are Coexpressed in the Dorsal Neural Tube at E9.5
(A–D and H) Frontal sections of E9.5 wild-type embryos.
(E–G) Frontal sections of E10.5 wild-type embryos.
(I–K) Frontal sections of E11.5 wild-type embryos.
(A), (E), and (I) display immunostaining for Pax3. (B), (F), and (J) depict immunostaining for Yap65. (C), (G), and (K) display immunostaining for phospho-Yap. At
E9.5 (A and B), Pax3 and Yap are colocalized in the dorsal neural tube (arrowhead), dorsal root ganglion (asterisks), and somites (arrows). Higher-magnification
Pax3/Yap merged images of the dorsal neural tube (D) and somite (H) display the high level of overlap of Pax3 and Yap. In (A)–(C), (E)–(G), and (I)–(K), scale bars
represent 100 mm. In (D) and (H), scale bars represent 50 mm.activator of melanogenesis regulated by Pax3 (Watanabe et al.,
1998) (Figure 5A). However, in double-knockout embryos, Mitf
expression was markedly downregulated in these neural crest
derivatives (Figure 5B). Quantitation of red fluorescent protein
(RFP)/Mitf-positive cells adjacent to and within the surface ecto-
derm revealed a significant decrease in the percentage of RFP+
cells that also expressed Mitf in Yap65/Taz null embryos (Fig-
ure 5C). In mouse embryonic fibroblasts derived from Tazflox/flox;
Yapflox/flox embryos, treatment with a Cre virus to delete both al-
leles of Yap65 and Taz produced a significant decrease in Mitf
expression (Figure 5D). Dopachrome tautomerase (Dct) is a
direct transcriptional target of Mitf (Lang et al., 2005) and was
similarly decreased following deletion of Yap65 and Taz (Fig-
ure 5D). We sought to determine if altered Mitf expression in
Yap/Taz double-knockout embryos was due to loss of synergy
between Pax3 and Yap/Taz or if this was a result of Tead-depen-
dent Yap/Taz gene regulation. Regulatory elements controlling
Mitf expression have been extensively characterized previously
(Watanabe et al., 1998; Bondurand et al., 2000; Potterf et al.,
2000). Both Pax3 and Pax7 can synergize with Taz and Yap65
to activate a Mitf-luciferase reporter construct (Figures 5F and1888 Cell Reports 9, 1885–1895, December 11, 2014 ª2014 The Aut5G). Although 18 potential Tead binding sites are located in the
Mitf promoter/enhancer region included in this assay (Figure 5E),
DN-Tead1 failed to significantly impair synergistic Pax-Taz/
Yap65 coactivation (Figures 5H and 5I), suggesting that Mitf acti-
vation by Pax3 and Taz is Tead independent.
Two Pax3 paired-domain binding sites have been described
within this Mitf enhancer: site P1 at position 260 to 244 and
site P2 at position40 to26 upstream of the transcription start
site (Watanabe et al., 1998; Bondurand et al., 2000; Potterf et al.,
2000). Sequence analysis utilizing the TRANSFAC database
identified an additional previously uncharacterized potential
Pax3 binding site, which we termed P3, located at position
160 to 143 relative to the transcription start site. A 519 bp
fragment of the Mitf enhancer, which contains the P1, P2, and
P3 sites, retained the ability to be synergistically activated by
Pax3 with Taz or Yap65 with activity comparable to the full-
length Mitf reporter (Figure S4). Each Pax3 binding site was
then evaluated individually in 100–200 bp Mitf promoter/
enhancer fragments. Fragments containing P2 and P3 exhibited
coactivation with Taz and Yap65, but the coactivation at site P1
was not significant in the context of the enhancer fragment.hors
Table 1. Genotyping Results of the Wnt1-Cre;Tazflox/+;Yapflox/+ x Tazflox/flox;Yapflox/flox Cross
Age
Genotype Wnt1-Cre;Tazflox/+;Yapflox/+ x Tazflox/flox;Yapflox/flox Cross
Total c2
Tazflox/+;
Yapflox/+
Tazflox/flox;
Yapflox/+
Tazflox/+;
Yapflox/flox
Tazflox/flox;
Yapflox/flox
Wnt1-Cre;
Tazflox/+;
Yapflox/+
Wnt1-Cre;
Tazflox/flox;
Yapflox/+
Wnt1-Cre;
Tazflox/+;
Yapflox/flox
Wnt1-Cre;
Tazflox/flox;
Yapflox/flox
E9.5 14 7 8 12 8 8 8 8 73 N/S
E10.5 5 7 10 4 7 7 4 13a 57 N/S
E11.5 5 10 8 2 9 6 7 0 47 0.0493
P10 12 8 14 18 15 9b 0 0 76 0.0001
N/S, not significant.
aCraniofacial abnormalities (13/13)
bCraniofacial hemorrhage (5/9)Mutation of the Pax3 binding sites within P2 and P3 led to a sta-
tistically significant decrease in the observed coactivation with
Taz and Yap65. The P2 and P3 fragments each contain a single
predicted Tead binding site, but DN-Tead1 did not significantly
decrease Pax3-Taz or Pax3-Yap65 coactivation of the P2, P3,
or 519 bp Mitf reporter (Figure S5). Taken together, we interpret
these results to indicate that P2 and P3, but not P1, act as dock-
ing sites for a Pax3-Taz/Yap65 coactivation complex.
Hippo Kinases Mst1 and Lats2 Can Inhibit Pax3-Taz/
Yap65 Synergistic Activation
Taz and Yap65 are downstream effectors of the Hippo signaling
pathway that is composed of a series of regulatory protein ki-
nases, including Mst and Lats. Activation of the Hippo pathway
culminates in phosphorylation of Taz/Yap65, which induces
translocation to the cytoplasm and abrogation of nuclear fun-
ctions. Serine residue 89 of the Taz protein was previously
demonstrated to be a critical residue for Lats kinase phosphory-
lation (Lei et al., 2008). Upon mutation to alanine, TazS89A gains
resistance to Lats regulation and is constitutively nuclear (Lei
et al., 2008). When Pax3 was coexpressed with TazS89A, there
was over 130-fold activation of a Pax3 reporter (Figure 6A),
consistent with constitutive activation. TazS89A was even
more potent than wild-type Taz, suggesting basal activity of Hip-
po signaling under these experimental conditions.
We probed the ability of upstream Hippo kinases Mst1 and
Lats2 to modulate Pax3-Taz/Yap65 transcriptional synergy.
Both Mst1 and Lats2 inhibited Pax3-Taz and Pax3-Yap65 coac-
tivation (Figures 6B–6E). Kinase inactive mutants of Mst1 or
Lats2, Mst1KI (Mst1-K59R) or LATS2KI (LATS2-D809A), respec-
tively, were relatively ineffective at inhibiting Pax3-Taz and Pax3-
Yap65 coactivation (Figures 6B–6E). Immunoblot analysis
confirmed that the wild-type and kinase inactive forms of each
Hippo kinase were expressed at equivalent protein levels (Fig-
ures 6F and 6G). LATS2 also significantly inhibited coactivation
of the endogenous Mitf enhancer by Pax3-Taz/Yap65 (Figures
6H–6I). In contrast, expression of LATS2KI did not alter Pax3-
Taz or Pax3-Yap65 coactivation at the Mitf enhancer (Figures
6H and 6I). Thus, transcriptional synergy between Pax factors
and Yap/Taz can be modulated by upstream regulators of the
Hippo pathway.
We further examined the ability to Pax3 and Pax7 to coactivate
another previously described Pax target gene. Myf5 is a regu-Cell Relator of myogenic determination that is another example of a
direct transcriptional target of Pax3/7 (Bajard et al., 2006).
Pax3 and Pax7 each functioned with Taz or Yap65 to coactivate
a previously described Myf5 enhancer (Figures S6A–S6C). This
activation was Tead independent, as the presence of DN-
Tead1 did not alter the coactivation (Figures S6D and S6E).
Further Lats2, but not Lats2KI, significantly inhibited Pax3-Taz/
Yap65-mediated activation of the Myf5 reporter (Figures S6F
and S6G).
DISCUSSION
Hippo signaling is a critical regulator of proliferation and EMT
during development and in cancer (Lei et al., 2008). In this study,
we demonstrate that the downstream effector molecules of Hip-
po signaling, Taz and Yap65, can function as coactivators of
Pax3. This complex requires Pax3 to act as theDNAbindingmoi-
ety and is regulated by upstream Hippo kinases. Unlike canoni-
cal Hippo signaling, the Pax3-Taz/Yap65 complex does not
require Tead factors to mediate activity. Deletion of Taz and
Yap65 in premigratory neural crest resulted in craniofacial de-
fects, similar to those seen in the absence of Pax3 and Pax7
(Mansouri and Gruss, 1998), and downregulation of the Pax3
target, Mitf. In vitro data suggest that another Pax3 target,
Myf5, can also be coordinately regulated by Pax3 and Yap/Taz.
It remains unclear if all Pax targets will require Yap65 or Taz for
functional activation or if a subset of physiologic target genes are
Yap/Taz independent. Clearly, many Yap/Taz targets are Pax in-
dependent and rely on Tead factors to mediate DNA binding. It is
likely that Pax factors can activate (or repress) some down-
stream pathways in the absence of Yap/Taz, while a subset of
targets are strongly coactivated in the presence of both Pax
and Yap/Taz. Further delineation of the various classes of down-
stream-regulated genes will be important to define the extent of
Pax/Hippo coordinate regulation.
The Pax3-Taz/Yap65 complex produces potent transcrip-
tional activation. In vivo, this complex is likely to include addi-
tional factors that may vary with context. Candidates include
the previously identified Pax3/7 binding protein, Pax3/7BP,
which recruits an H3K4 histone methyltransferase to target
gene promoters (Diao et al., 2012). Taz has been shown to
interact with the histone acetyl transferases PCAF and p300
(Murakami et al., 2005). This interaction greatly enhances Tazports 9, 1885–1895, December 11, 2014 ª2014 The Authors 1889
Figure 3. Taz and Yap65 Are Required for
Normal Neural Crest Development
Whole-mount bright-field images (A, C, E, F, I, J, M,
N, Q, and R) and H&E-stained transverse sections
(B, D, G, H, K, L, O, P, S, and T) of representative
embryos of the indicated genotypes at E9.5 (A–D)
and E10.5 (E–T). Arrowheads in (M), (N), and (Q)–(T)
indicate regions of abnormal facial mesenchyme.
ba, branchial arches. Scale bars, 100 mm.transcriptional activity at an atrial natriuretic factor promoter re-
porter construct (Murakami et al., 2005). Future studies will eluci-
date the nature of additional Pax/Taz/Yap complex subunits.
Since Pax factors from all Pax families can utilize Taz and
Yap65 as coactivators, Hippo signaling could be a common
means to regulate activity of many Pax target genes in diverse
developmental contexts. Pax genes function in multiple devel-
oping tissues and play key roles in organogenesis. Pax6, for1890 Cell Reports 9, 1885–1895, December 11, 2014 ª2014 The Authorsexample, is critical for formation of the
eye and is mutated in inherited causes
of blindness. Pax2 functions in early kid-
ney formation, Pax8 functions in the
thymus and has also been shown to coac-
tivate with Taz, and Pax1/9 functions in
the skeleton (Di Palma et al., 2009). Hippo
signaling is known to regulate organ size.
The functional interaction of Pax proteins
with Yap65 and Taz may provide a phys-
ical and functional mechanism to link
organogenesis with the regulation of or-
gan size. Likewise, disruption of Pax func-
tion has been implicated in cancer, and
the role of Pax/Hippo synergy in onco-
genesis will be an important area of future
investigation.
EXPERIMENTAL PROCEDURES
Plasmids
The firefly-luciferase reporter construct 5xPax3BS
was provided by M. Buckingham (Relaix et al.,
2003) and subcloned into pGL4.27 (Promega).
To generate a Pax3-homeodomain reporter con-
struct, a previously identified Pax homeodomain-
binding motif (Soleimani et al., 2012), TAATT-
GATTA, was synthetically generated and reiterated
nine times. This sequence was then cloned up-
stream of pGL4.27 for use in luciferase assays
(Promega). AnMITF reporter previously published,
containing approximately 2 kb of the 50 proximal
human promoter (chr3:69,934,337-69,936,682
[hg38]; Lang et al., 2005) was subcloned into
pGL4.27 (Promega). 8xGTIIC, a Tead reporter,
was provided by S. Piccolo (Dupont et al., 2011;
Addgene plasmid 34615). Murine Taz and Taz-
S89A expression vectors were described previ-
ously (Kanai et al., 2000; Addgene plasmids
19025 and 19026) and were subcloned into
pCMV-Sport6 (Invitrogen). Murine Yap65 was ex-
pressed in pCMV-Sport6 (Invitrogen) as described
previously (Milewski et al., 2004). Dominant-nega-tive human TEAD1 (DN-TEAD1) was provided by Kun-Liang Guan (Zhang
et al., 2009; Zhao et al., 2008). Murine hippo kinases Mst1 and Mst1-KI were
previously described (Lin et al., 2002; Addgene plasmids 1965 and 1966).
Expression plasmids for human hippo kinases LATS2 and LATS2-KIwere pro-
vided by D. Pan (Dong et al., 2007). ThemurinePax3 expression construct was
previously described (Lang et al., 2000) and was subcloned into pCMV-Sport6
(Invitrogen). The murine Pax3 paired-domain mutant (Pax3-PD Mutant) con-
tains a single cytosine to thymine mutation that produces a proline to leucine
change at amino acid 50, which prevents Pax3 binding to DNA sequences,
Figure 4. Characterization of Embryos Lacking Taz and Yap65
(A and B) Wnt1-Cre; Taz flox/+ ;Yap flox/+; R26Tom/+ E10.5 embryo imaged in bright field (A) and fluorescence (B).
(C) Transverse sections of E10.5 Wnt1-Cre; Taz flox/+ ;Yap flox/+; R26Tom/+ embryo stained tdTomato (RFP) and Pax3.
(D and E) Wnt1-Cre; Taz flox/flox;Yap flox/flox; R26Tom/+ E10.5 embryo imaged in bright field (D) and fluorescence (E).
(F) Transverse sections of E10.5 Wnt1-Cre; Taz flox/flox;Yap flox/flox; R26Tom/+ embryo stained for tdTomato (RFP) and Pax3.
(G–K) Transverse sections of E10.5 Wnt1-Cre; Taz flox/+ ;Yap flox/+;R26Tom/+ embryos stained for tdTomato (RFP) (G and H), tdTomato (RFP) and neurofilament
(2H3) (I and J), or tdTomato (RFP) and Sox10 (K).
(L–P) Transverse sections of E10.5Wnt1-Cre; Taz flox/flox ;Yap flox/flox;R26Tom/+ embryos stained for tdTomato (RFP) (L and M), tdTomato (RFP) and neurofilament
(2H3) (N and O), or tdTomato (RFP) and Sox10 (P).
Arrows in (C) and (F) designate costaining in the dorsal neural tube. Branchial arches (ba) are invested with red-fluorescingWnt1-derived neural crest (A, B, D, and
E). Arrows in (I) and (N) mark dorsal root ganglia, while asterisks demark the right and left sympathetic trunks. Circled areas in (J) and (O) denote the glosso-
pharyngeal (IX) preganglion. ba, branchial arches; lb, limb bud; nt, neural tube; eg, enteric ganglia. Imagesweremerged after global adjustment for brightness and
were produced by combining respective red and green channels using Photoshop software (Adobe). Scale bars, 100 mm.was previously described (Epstein et al., 1995) and was subcloned into pCMV-
Sport6 (Invitrogen). Human PAX7 was expressed in pcDNA3 (Invitrogen).
Cell Culture and Luciferase Assay
HEK293T cells were maintained at 37C with 5% CO2 in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum, penicillin,
and streptomycin. All HEK293T cell transfections were completed using
FuGene6 (Roche). Experiments utilized 250 ng of the specified firefly-lucif-
erase reporter constructs, 80 ng Taz/Yap65, 40 ng Pax expression vector,
and 75 ng pGL2-Basic-renilla luciferase (Promega). In experiments with
Mst1, Mst1-KI, LATS2, or LATS2-KI, 120 ng of the kinase expression vector
was included. All transfections maintained an equal concentration of total
DNA with the inclusion of the pCMV-Sport6 empty vector (Invitrogen). Cellular
extracts were collected 48 hr posttransfection for use in a dual-luciferase
assay (Promega). Twenty microliters of cellular extract was used to assess
firefly and renilla luciferase activities and luciferase activity was normalized
to the renilla activity. All experiments were performed in duplicate on at least
three separate occasions. Statistical differences between conditions were
analyzed using ANOVA, with a Tukey-Kramer post hoc comparison test.Cell ReWestern Blot
HEK293T cells were transfected with 2 mg of the specified Hippo kinase:
Mst1, Mst1KI, LATS2, LATS2-KI. Mst1 and Mst1KI contain an N-terminal
FLAG epitope tag, while LATS2 and LATS2KI contain an N-terminal myc
epitope tag. A nontransfected plate of cells was processed in parallel as a
control. A total of 48 hr posttransfection, cells were lysed in RIPA buffer
(150 mm NaCl, 50 mm Tris-Base [pH 7.5], 1% IGEPAL, 0.5% sodium deox-
ycholate, 0.1% SDS) plus protease inhibitors (Complete Mini, Roche). All ly-
sates were quantitated with a BCA Assay (Promega) and an equal amount of
total protein was loaded per well of a 4%–12% gradient gel and run at 120 V
for 2 hr. Blots were transferred overnight at 4C, at 20 V onto a polyvinylidene
fluoride membrane (Invitrogen). Membranes were blocked in 10% nonfat dry
milk/Tris-buffered saline and Tween 20 and incubated in primary antibody
overnight: M2-FLAG (mouse monoclonal, Sigma), myc (mouse monoclonal,
Cell Signaling #2276), or actin (rabbit polyclonal, Cell Signaling, #4970).
All blots were probed with horseradish peroxidase-conjugated secondary
antibody for 1 hr with either anti-mouse secondary (Cell Signaling) or anti-
rabbit secondary (Cell Signaling). Blots were developed using ECL Prime
(Amersham).ports 9, 1885–1895, December 11, 2014 ª2014 The Authors 1891
Figure 5. Mitf Is Coordinately Regulated by Pax3 and Yap/Taz
(A and B) Fluorescent images of transverse sections of E10.5 embryos immunostained for Mitf and tdTomato (RFP). (A) Colabeled cells adjacent to surface
ectoderm where migrating melanoblasts are normally found are indicated by arrowheads. (B) Migratory neural crest cells near the ectoderm that do not express
Mitf in double-mutant embryos are indicated by arrowheads. Scale bars, 100 mm.
(C) Quantitation of RFP/Mitf expressing cells adjacent to and in the surface ectoderm of control (Ctl.) and Yap65/Taz double-null embryos (Null). Data depicted are
the average percentage of RFP+ cells that also express Mitf + SEM. A minimum of 60 cells were quantified from both control and null animals encompassing
sections from three individual control and null embryos. Images were merged after global adjustment for brightness and were produced by combining respective
red and green channels using Photoshop software (Adobe).
(D) Quantitative real-time PCR of untreated or Cre-virus treated Tazflox/flox;Yapflox/flox mouse embryonic fibroblasts for Mitf, Dct, Taz, and Yap65. Data are the
mean + SEM.
(E) Schematic representation of a Mitf luciferase reporter plasmid. Pax3 binding sites are denoted within gray oblong circles. Predicted TEAD binding sites are
denoted with white ovals, representing the consensus sequence XDGHATXT, where X = A, T, C, or G; D = A or T; and H = A, T, or C (Anbanandam et al., 2006).
(F) Results of dual luciferase reporter assays in HEK293T cells with Mitf-luciferase reporter in the presence (+) or absence () of Pax3, Taz or Yap65.
(G) Results of dual luciferase reporter assays in HEK293T cells with Mitf-luciferase reporter in the presence (+) or absence () of Pax7, Taz or Yap65.
(H) Results of dual luciferase reporter assays in HEK293T cells with Mitf-luciferase reporter in the presence (+) or absence () of Pax3, Taz or the specified
nanogram (ng) amount of DN-Tead1.
(I) Results of dual luciferase reporter assays in HEK293T cells with Mitf-luciferase reporter in the presence (+) or absence () of Pax7, Taz or the specified
nanogram amount of DN-Tead1.
Statistics in (C) and (D) were completed using a Student’s t test (**p < 0.01, ***p < 0.001). In all experiments, luciferase activity was first normalized to the activity of
a cotransfected renilla luciferase construct, then to the activity observed in the absence of specified cDNAs (lane 1). All experiments were performed in duplicate a
minimum of three individual occasions. Data depicted in (F)–(I) are the mean + SEM. Statistics were completed using an ANOVA with a Tukey-Kramer post hoc
comparison test. ***p < 0.001Histology and Immunofluorescence
Samples were harvested, fixed overnight in 4% paraformaldehyde, and dehy-
drated through an ethanol series. All samples were paraffin embedded and
sectioned. Antibodies used for immunofluorescence were anti-Pax3 mouse
monoclonal (developed by C.P. Ordahl and obtained from the Developmental
Studies Hybridoma Bank, created by The Eunice Kennedy Shriver National
Institute of Child Health and Human Development [NICHD] of the NIH), anti-
Yap rabbit polyclonal (Cell Signaling #4912S), anti-phospho-Yap rabbit
polyclonal (Cell Signaling #4911), anti-neurofilament (2H3, developed by T.
M. Jessell and J. Dodd obtained from the Developmental Studies Hybridoma1892 Cell Reports 9, 1885–1895, December 11, 2014 ª2014 The AutBank, created by the NICHD of the NIH), anti-Mitf (Vector Laboratories, clone
34CA5), anti-Sox10 (Santa Cruz Biotechnology, N-20), and anti-RFP (Rock-
land Immunochemicals, #600-401-379). Hematoxylin and eosin (H&E) staining
was completed using a standard protocol.
Melanocyte Quantitation
Transverse sections from Wnt1-Cre;Taz flox/+ ;Yap flox/+;R26Tom/+ and Wnt1-
Cre;Taz flox/flox;Yap flox/flox;R26Tom/+ E10.5 embryos were costained for RFP
and Mitf. Cells greater than 100 mm from the surface ectoderm were excluded
from analysis. Seven sections from three independent embryos were includedhors
Figure 6. Hippo Kinases Mst1 and Lats2 Can Inhibit the Activity of the Pax3-Taz/Yap Complex
(A) Results of dual luciferase reporter assays in HEK293T cells with Pax3-PD-luciferase reporter in the presence (+) or absence () of Pax3, Taz, or constitutively
active Taz, TazS89A.
(B) Results of dual luciferase reporter assays in HEK293T cells with Pax3-PD-luciferase reporter in the presence (+) or absence () of Pax3, Taz, Mst1, or a kinase-
inactive form of Mst1, Mst1KI.
(C) Results of dual luciferase reporter assays in HEK293T cells with Pax3-PD-luciferase reporter in the presence (+) or absence () of Pax3, Yap65, Mst1, or
Mst1KI.
(D) Results of dual luciferase reporter assays in HEK293T cells with Pax3-PD-luciferase reporter in the presence (+) or absence () of Pax3, Taz, Lats2, or Lats2KI.
(E) Results of dual luciferase reporter assays in HEK293T cells with Pax3-PD-luciferase reporter in the presence (+) or absence () of Pax3, Yap65, Lats2, or
Lats2KI.
(F) Anti-FLAGwestern blot from HEK293T cells either nontransfected (NT) or transfected with a FLAG-taggedMst1 or FLAG-tagged Mst1KI. Western blots of the
same cellular protein lysates were also probed with anti-actin to demonstrate equivalent protein loading among samples.
(G) Anti-myc western blot from HEK293T cells either nontransfected (NT), transfected with a myc-tagged Lats2, or transfected with a kinase-inactive form of
Lats2, a myc-tagged Lats2KI. Western blots of the same cellular protein lysates were also probed with anti-actin to demonstrate equivalent protein loading
among samples.
(H) Results of dual luciferase reporter assays in HEK293T cells with Mitf-luciferase reporter in the presence (+) or absence () of Pax3, Taz, Lats2, or Lats2KI.
(legend continued on next page)
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in the analysis, which totaled 60 RFP+ cells in control embryos and 62 RFP+
cells in null embryos. Data are reported as an average percentage of each field
totaled + SEM. Statistical differences between conditions were analyzed using
a Student’s t test.
Mouse Embryo Fibroblast Preparation
Mouse embryo fibroblasts (MEFs) were isolated from E14.5 Tazflox/flox;
Yapflox/flox embryos as described previously (Connor 2000). Briefly, E14.5 em-
bryos were collected, the heads and internal organs were removed, and the re-
mains were washed twice in PBS. Embryos were then dissociated by passage
through a 16G needle and incubated in a trypsin solution for 5 min at 37C. The
resulting cells were then triturated and incubated for another 5 min at 37C,
and an equal volume of MEF media was added and incubated for 5 min at
room temperature. After centrifugation, the cell pellet was resuspended in
MEF media, plated, and incubated at 37C. Cells were grown to confluence,
then trypsinized and replated for treatment. In order to delete the floxed Taz
and Yap65 alleles, MEFs were treated for 48 hr with an adeno-associated virus
expressing a constitutively active Cre recombinase (AAV1-CMV-Cre, Penn
Vector Core, University of Pennsylvania).
RNA Isolation, cDNA Synthesis, and Quantitative Real-Time PCR
RNA was harvested from a 1–100 mm dish of untreated or AAV1-CMV-Cre-
treated Tazflox/flox;Yapflox/flox MEFs using the QIAGEN RNeasy kit following
the manufacturer’s instructions (QIAGEN). cDNAwas synthesized with the Su-
perscript III system (Invitrogen). Quantitative real-time PCR was performed in
triplicate with SYBR green reagents (Applied Biosystems). Relative gene
expression was normalized to Gapdh. Quantitative real-time PCR primer se-
quences are as follows:
Mitf forward: 50-CGAGCTCATGGACTTTCCCTTA-30
Mitf reverse: 50-CTTGATGATCCGATTCACCAAA-30
DCT forward: 50-TTCGCAAAGGCTATGCGC-30
DCT reverse: 50-GTTACTACCCAGGTCAGGCCAG-30
Taz forward: 50-GAGAGGATTAGGATGCGTCAAG-30
Taz reverse: 50-GGATCTGAGCTACTGTTGGTG-30
Yap forward: 50-ACCATAAGAACAAGACCACATCC-30
Yap reverse: 50-CTTCACTGGAGCACTCTGAG-30
Gapdh forward: 50-CGTCCCGTAGACAAAATGGT-30
Gapdh reverse: 50-GAATTTGCCGTGAGTGGAGT-30.Mice
All mice were maintained on a mixed genetic background. Wnt1-Cre (Jiang
et al., 2000), Yapflox/+ (Xin et al., 2011), and Tazflox/+ (Xin et al., 2013) alleles
were genotyped as previously described. The Yapflox/+ and Tazflox/+ alleles
were developed in the laboratory of Dr. Eric N. Olson at the University of Texas
Southwestern Medical Center (Dallas, TX). R26tdTomato mice (B6.Cg-
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J) were obtained from Jackson
Labs (strain number 007914). All animal protocols were approved by the Uni-
versity of Pennsylvania Institutional Animal Care and Use Committee.
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